AU2019211326B2 - B7-H4 antibodies and methods of use thereof - Google Patents

B7-H4 antibodies and methods of use thereof

Info

Publication number
AU2019211326B2
AU2019211326B2 AU2019211326A AU2019211326A AU2019211326B2 AU 2019211326 B2 AU2019211326 B2 AU 2019211326B2 AU 2019211326 A AU2019211326 A AU 2019211326A AU 2019211326 A AU2019211326 A AU 2019211326A AU 2019211326 B2 AU2019211326 B2 AU 2019211326B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
antigen binding
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019211326A
Other languages
English (en)
Other versions
AU2019211326A1 (en
Inventor
Dallas Benjamin Flies
Solomon Langermann
Linda Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NextCure Inc
Original Assignee
NextCure Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NextCure Inc filed Critical NextCure Inc
Publication of AU2019211326A1 publication Critical patent/AU2019211326A1/en
Application granted granted Critical
Publication of AU2019211326B2 publication Critical patent/AU2019211326B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019211326A 2018-01-23 2019-01-23 B7-H4 antibodies and methods of use thereof Active AU2019211326B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620545P 2018-01-23 2018-01-23
US62/620,545 2018-01-23
PCT/US2019/014748 WO2019147670A1 (en) 2018-01-23 2019-01-23 B7-h4 antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
AU2019211326A1 AU2019211326A1 (en) 2020-09-10
AU2019211326B2 true AU2019211326B2 (en) 2025-11-27

Family

ID=67396234

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019211326A Active AU2019211326B2 (en) 2018-01-23 2019-01-23 B7-H4 antibodies and methods of use thereof

Country Status (11)

Country Link
US (1) US12286478B2 (https=)
EP (1) EP3743447B1 (https=)
JP (2) JP2021512151A (https=)
KR (1) KR20200112913A (https=)
CN (2) CN112566934B (https=)
AU (1) AU2019211326B2 (https=)
BR (1) BR112020014929A2 (https=)
CA (1) CA3089469A1 (https=)
DK (1) DK3743447T3 (https=)
ES (1) ES2980171T3 (https=)
WO (1) WO2019147670A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112566934B (zh) 2018-01-23 2024-09-17 奈斯科尔公司 B7-h4抗体及其使用方法
JP7264337B2 (ja) * 2019-03-21 2023-04-25 スージョウ カノヴァ バイオファーマシューティカル カンパニーリミテッド 抗ｂ７ｓ１ポリペプチドおよびその使用
TWI821699B (zh) * 2020-06-30 2023-11-11 大陸商諾納生物（蘇州）有限公司 抗b7h4抗體及其雙抗和應用
JP2024501894A (ja) 2021-01-04 2024-01-16 メルサナ セラピューティクス インコーポレイテッド Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法
MX2023011310A (es) 2021-03-26 2023-10-05 Innate Pharma Anclajes de citocina para proteinas de celulas nk de union a nkp46.
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2024208818A1 (en) 2023-04-04 2024-10-10 Innate Pharma Modular chimeric antigen receptor
WO2025128735A2 (en) * 2023-12-11 2025-06-19 Nextcure, Inc. B7-h4 antibody-drug conjugates and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087416A1 (en) * 2000-07-27 2009-04-02 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
WO2009073533A2 (en) * 2007-11-30 2009-06-11 Medarex, Inc. Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US20150315275A1 (en) * 2012-12-19 2015-11-05 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
WO2016070001A1 (en) * 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5190929A (en) 1988-05-25 1993-03-02 Research Corporation Technologies, Inc. Cyclophosphamide analogs useful as anti-tumor agents
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US7411051B2 (en) 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
ATE413466T1 (de) 1998-09-02 2008-11-15 Diadexus Inc Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
US7052694B2 (en) 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
DK1633784T3 (da) 2003-05-09 2011-10-24 Diadexus Inc OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
US20070166281A1 (en) 2004-08-21 2007-07-19 Kosak Kenneth M Chloroquine coupled antibodies and other proteins with methods for their synthesis
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN101355965A (zh) 2005-06-08 2009-01-28 达纳－法伯癌症研究院 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2007056539A2 (en) 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
EP2345412A1 (en) 2005-12-02 2011-07-20 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
EP2109455A2 (en) 2006-12-27 2009-10-21 The Johns Hopkins University Compositions and methods for stimulating an immune response
CN103536915A (zh) 2006-12-27 2014-01-29 埃默里大学 用于治疗传染病和肿瘤的组合物和方法
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
WO2011026122A2 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. B7-h4 fusion proteins and methods of use thereof
JP6120848B2 (ja) 2011-08-15 2017-04-26 メディミューン，エルエルシー 抗ｂ７−ｈ４抗体およびその使用
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
RU2015114772A (ru) 2012-09-21 2016-11-10 Санофи Производные амида бензоимидазол-карбоновой кислоты в качестве модуляторов рецептора apj
AU2014244424A1 (en) 2013-03-14 2015-08-27 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
EP3177322A4 (en) 2014-08-08 2018-07-18 Alector LLC Anti-trem2 antibodies and methods of use thereof
CN112566934B (zh) 2018-01-23 2024-09-17 奈斯科尔公司 B7-h4抗体及其使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090087416A1 (en) * 2000-07-27 2009-04-02 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
WO2009073533A2 (en) * 2007-11-30 2009-06-11 Medarex, Inc. Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
US20150315275A1 (en) * 2012-12-19 2015-11-05 Amplimmune, Inc. Anti-human b7-h4 antibodies and their uses
WO2016070001A1 (en) * 2014-10-31 2016-05-06 Jounce Therapeutics, Inc. Methods of treating conditions with antibodies that bind b7-h4

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Qian, Y. et al., 'Development of a novel monoclonal antibody to B7-H4: characterization and biological activity', European Journal of Medical Research, (2011-07-25), vol. 16, no. 7, pages 295, doi: 10.1186/2047-783X-16-7-295. *

Also Published As

Publication number Publication date
JP2024075721A (ja) 2024-06-04
EP3743447A1 (en) 2020-12-02
JP2021512151A (ja) 2021-05-13
DK3743447T3 (da) 2024-05-27
CN112566934A (zh) 2021-03-26
US20210032346A1 (en) 2021-02-04
WO2019147670A1 (en) 2019-08-01
CN119097699A (zh) 2024-12-10
BR112020014929A2 (pt) 2020-12-08
RU2020127875A (ru) 2022-02-24
ES2980171T3 (es) 2024-09-30
US12286478B2 (en) 2025-04-29
KR20200112913A (ko) 2020-10-05
CN112566934B (zh) 2024-09-17
EP3743447B1 (en) 2024-03-27
AU2019211326A1 (en) 2020-09-10
CA3089469A1 (en) 2019-08-01
EP3743447A4 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
US20250084164A1 (en) Compositions and methods for modulating lair signal transduction
AU2019211326B2 (en) B7-H4 antibodies and methods of use thereof
US12209127B2 (en) Antibodies to programmed cell death protein 1
US20230357384A1 (en) Compositions and methods for modulating flrt3 mediated signal transduction
WO2025155809A2 (en) Compositions and methods for modulating vstm-1 mediated signal transduction
RU2809243C2 (ru) Антитела в7-н4 и способы их применения
AU2021293287A1 (en) Compositions and methods for modulating FLRT3 mediated signal transduction
RU2846895C2 (ru) Композиции и способы для модуляции передачи сигнала lair
RU2812915C2 (ru) Антитела к белку программируемой клеточной смерти 1
HK40040283A (en) B7-h4 antibodies and methods of use thereof
HK40040283B (en) B7-h4 antibodies and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)